# Kamada Ltd. (KMDA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $8.54, market value $493 million.

## Valuation
- **P/E (trailing): 22.5×** (5-yr avg 27.0×, 3-yr avg 27.0×). Kamada Ltd. trades at 22.5× trailing earnings, close to its own five-year average of 27.0×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 14.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.36**. A PEG of 0.36 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 10.1×**. Enterprise value is 10.1× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.3%**. Free cash flow equals 5.3% of the market value. Above 5% is generally attractive.
- **Earnings yield: 4.4%**. The inverse of the P/E: 4.4% of the price is earned each year.

## Profitability
- **Gross margin: 40.8%**. Kamada Ltd. keeps 40.8% of revenue after the direct cost of what it sells.
- **Operating margin: 14.5%**. 14.5% of revenue is left after running the business.
- **Net margin: 11.2%**. 11.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 7.5%**. 7.5% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 11.0%**. Return on all capital, debt included, is 11.0%.
- **Return on assets: 5.9%**. Each dollar of assets produces 5.9% of profit.

## Growth
- **Revenue growth (1 yr): 12.1%** (3-yr 11.7%/yr, 5-yr 6.3%/yr). Revenue grew 12.1% over the last year, against 6.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 40.0%** (5-yr -1.6%/yr). Earnings per share rose 40.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Kamada Ltd. holds more cash than debt.
- **Interest coverage: 26.8×**. Operating profit covers interest 26.8× over, a safe margin.
- **Current ratio: 4.07** (quick 4.07). Current assets cover the next year's liabilities 4.07 times.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.99%** ($0.25 per share, trailing). Kamada Ltd. yields 1.99%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 57%**. 57% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 1**. 1 straight year of increases.

## Price and momentum
- **Total return (1 yr): 24.6%** (YTD 24.6%, 3-mo 19.1%). The shares are up 24.6% over twelve months including dividends.
- **From 52-week high: -8.7%** (31.4% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 67**. An RSI of 67 is neutral.
- **Beta (1 yr): 1.04** (volatility 34%). Beta of 1.04 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KMDA · Page: https://foliofundamentals.com/stocks/kmda

Not investment advice.